Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy - Wikidata - awgldk - TriplyDB

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

http://www.wikidata.org/entity/Q36712243

about

Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture A multispecies approach for understanding neuroimmune mechanisms of stress.Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations.Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy Compliance to Care Guidelines for Duchenne Muscular Dystrophy.Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients Treatment of dystrophin cardiomyopathies.The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia.Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.Recent developments in Duchenne muscular dystrophy: facts and numbers.Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database.Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.Brazilian consensus on Duchenne muscular dystrophy. Part 1: diagnosis, steroid therapy and perspectives.Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies.Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy Impact of biobanks on research outcomes in rare diseases: a systematic review

P2860

Q28072269-F61DE3C3-D684-4EE7-B69F-D922C7F9D754 Q33721025-5172075F-F83C-4D1E-B542-9930732EC215 Q33856905-8437AC0A-9867-4201-856C-82FD270EE2D2 Q33870621-27353DD0-DA5D-4426-9D2C-A12BEEBCD89D Q34332718-4501E5F5-B179-4095-BD33-583AFE867214 Q35508913-E8318ED4-781E-477D-BEBF-7596416F44BD Q35740280-8F755A22-978D-4DC6-8939-29A94C41B857 Q36069707-6FCE575D-ACF2-4146-9192-32F68D957586 Q36155677-B9DD0337-B9B8-4A3F-B8D9-81EAFF81433E Q36327073-4A8D6E42-6379-4CB1-B574-21673A3E5772 Q36560420-FBE749DF-85FC-415E-BB95-538FEC977473 Q37349765-90AD14EE-A74F-4F3E-9791-CC108BB73C29 Q38178061-523443E4-95D3-4BD6-A501-A3F5169C389A Q38406108-EDCE6FF9-3C91-4A66-882F-1917739D273D Q39629598-7BD6E5CE-0847-47E6-9320-9CD9ADF74A82 Q40955126-33F1192D-9DE9-4CDF-80AE-4058399C90A4 Q45174751-B4C865AB-100C-416E-8B34-29561F092244 Q45874288-BABC9A3B-D29C-4441-9EAE-BCDB843545EF Q47324398-506DDC44-6959-4B5B-9079-D58EF8BCD982 Q48604144-F12C29B9-C6D4-4CF9-9B46-34A512232227 Q51138095-3756CF9C-DE82-4717-85F3-0E185DEBBB5E Q58476250-E9105FE1-E21F-48FB-93BF-355850C75364 Q59127575-9D140634-AD0A-4B91-B1D0-791D90A43131

P2860

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

http://www.wikidata.org/entity/Q36712243

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@ast

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@en

type

label

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@ast

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@en

prefLabel

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@ast

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@en

P1433

Q36712243-FDCE5D47-2B9B-4CBA-8A12-2EFD49B5870B

P1476

Q36712243-943FE63F-3B83-4D11-8337-D0496676E5B6

P2093

Q36712243-3F4379B1-B5D0-4E7B-B436-0ABC5F929441

Q36712243-B3A7C7A6-7BAF-435E-9B34-67BCAAB5A587

Q36712243-B901EBA2-D5C0-4F5C-9F14-D0FCFD893E17

Q36712243-C7A2C349-3091-43AC-9A84-89F7DB5317AD

Q36712243-D557B641-DFE9-45D0-B7F8-9205972616C0

Q36712243-DA981480-D38A-441C-9D8D-BE444A3ACC2B

P2860

Q36712243-003D7E34-DB69-4FED-9AFE-92E93251E6A8

Q36712243-0AA83BA1-1C8B-4AB7-B496-15F4534BFA3F

Q36712243-2C075669-4C8F-42A0-AFFD-F6BBB1DC1F8F

Q36712243-2EFF8461-3DFB-42F2-AE97-9992D19E7453

Q36712243-30D8A819-857C-4020-B280-E7B58BDE5996

Q36712243-45366B6C-56A0-48D6-8EE5-6A1149B8F8A9

Q36712243-49A57CB5-23E9-4800-890C-42EF32BA7F08

Q36712243-4C319358-882E-49E8-B17D-B50A74BFE541

Q36712243-4EA54600-6E12-473D-AD11-F558EFB31206

Q36712243-640E9E30-8872-4329-B3BA-AF24C7597D8F

P304

Q36712243-54FB1BDC-ECDE-498D-A6ED-0BF1AF908A2B

P31

Q36712243-F447AD2B-CC41-4A6B-9BEF-FC0D654E9BAE

P356

Q36712243-0F46DFC0-9855-4ABE-A9F0-9ED56F2ED0DA

P433

Q36712243-1ADCCE21-B15E-4161-9B2A-506FA00D895C

P478

Q36712243-C951C372-E54B-455E-A773-37C0AD53FC2C

P50

Q36712243-E2A085C0-6456-46AF-A3C0-DB2E7D676A0E

P577

Q36712243-2F2F60E2-0C07-4A1C-A34C-03C9B8BF00BB

P5875

Q36712243-001FAD36-B79B-4F0E-A2A4-BFB197C8A3AE

P698

Q36712243-14F38DB3-4E09-47E0-98CC-C2FE91B39371

P932

Q36712243-E061C7E8-177F-4D42-AE6B-6F859F5423AB

P356

J.PMR.2012.08.003

P1433

Physical medicine and rehabilitation clinics of North America

P1476

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

@en

P2093

Edward M Connor

http://www.w3.org/2001/XMLSchema#string

Eric P Hoffman

http://www.w3.org/2001/XMLSchema#string

Erica Reeves

http://www.w3.org/2001/XMLSchema#string

Jesse Damsker

http://www.w3.org/2001/XMLSchema#string

John M McCall

http://www.w3.org/2001/XMLSchema#string

Kate Bushby

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection.

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord I

Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

P304

821-828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PMR.2012.08.003

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Kanneboyina Nagaraju

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233383664

http://www.w3.org/2001/XMLSchema#string

P698

23137739

http://www.w3.org/2001/XMLSchema#string

P932

3606917

http://www.w3.org/2001/XMLSchema#string